Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Iqbal

Internal Medicine Kinston, NC Medical Doctor

NPI 1043226574 CMS profile 364453

701 Doctors Dr, Suite N, Kinston, NC 28501

Open in the dashboard

General payments

$7,832

496 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Iqbal of Kinston, NC is reported in the CMS Open Payments database as having received $7,832 across 496 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,277 66
2024 General $1,647 104
2023 General $1,549 102
2022 General $1,663 107
2021 General $626 43
2020 General $397 27
2019 General $674 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Iqbal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohammad Iqbal were reported at $1,277. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohammad Iqbal Internal Medicine median Middle half National median
2019 $674 $159 $48–$570 $163
2020 $397 $119 $33–$402 $114
2021 $626 $135 $37–$521 $132
2022 $1,663 $141 $42–$496 $149
2023 $1,549 $149 $45–$519 $160
2024 $1,647 $154 $47–$537 $164
2025 $1,277 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $886 34 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $780 46 payments
  3. GlaxoSmithKline, LLC. $763 55 payments
  4. Novartis Pharmaceuticals Corporation $754 57 payments
  5. Novo Nordisk Inc $711 54 payments
  6. Lilly USA, LLC $489 34 payments
  7. Amgen Inc. $476 36 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $314 21 payments
  9. Sanofi-Aventis U.S. LLC $296 18 payments
  10. Merck Sharp & Dohme Corporation $225 14 payments
  11. Other $2,138 127 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,783 492 payments
  2. Education $49 4 payments
Products named General payments · program years 2019–2025
  1. Kerendia $780 46 payments
  2. FARXIGA $661 20 payments
  3. TRELEGY ELLIPTA $646 48 payments
  4. AIRSUPRA $462 10 payments
  5. LEQVIO $431 35 payments
  6. BREZTRI $417 4 payments
  7. Ozempic $379 29 payments
  8. RYBELSUS $353 25 payments
  9. Otezla $301 22 payments
  10. Repatha $258 19 payments
  11. Other $6,421 406 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 239 drugs

Part D claims

28,937

Median for Internal Medicine: 777

Drug cost

$2,811,692

Median for Internal Medicine: $73,373

Branded share of claims

22.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 368 $285,653
Ozempic Semaglutide Brand 243 $258,653
Farxiga Dapagliflozin Propanediol Brand 233 $202,425
Jardiance Empagliflozin Brand 202 $187,096
Linzess Linaclotide Brand 227 $176,662
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 170 $117,226
Rybelsus Semaglutide Brand 78 $110,235
Trulicity Dulaglutide Brand 83 $107,382
Januvia Sitagliptin Phosphate Brand 73 $75,496
Mounjaro Tirzepatide Brand 64 $67,242

The 10 drugs with the highest cost, of 239 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 119 billing codes

Paid by Medicare

$299,132

Of which drugs: $57,796

Medicare patients

435

Average age 74

Services billed

10,649

189 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 38%
Ischemic heart disease 29%
Chronic kidney disease 26%
Heart failure 21%
COPD 18%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 17 1,440 $29,724
Vaccine for influenza for injection into muscle 90662 Office 159 160 $11,264
Pcv20 vaccine im 90677 Office 11 11 $3,158
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 19 19 $416

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $215
$215 68 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $128
$128 — —
JARDIANCE
  • Lilly USA, LLC $86
  • Boehringer Ingelheim Pharmaceuticals, Inc. $31
$117 202 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $109
$109 170 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $100
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

496 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record